Previous 10 | Next 10 |
Concord, Mass.-based Adiso Therapeutics, an anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. Source: humphery / Shutterstock.com The U.S. Securities and Exchange Commission (SEC) spe...
Chinese tech stocks were hammered on potential delisting fears. However, we believe that the market reaction was unwarranted. We believe Alibaba and JD.com look attractive now. For further details see: Alibaba And JD.com: Chinese Tech Stocks Hit By Delisting Fears, China...
U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO. Company’s shares have tumbled more than 40% on the developments, even as it reported strong revenue gains for 2021...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Inflation gets worse Check out Wall Street Breakfast's new Seeking Alpha show The Weekend Bite! On this week's episode we discuss the one stock to buy righ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Acco...
Chinese Internet stocks such as JD.com (NASDAQ:JD), Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU) dove into the red, Thursday, as the Securities and Exchange Commission named five companies from China that could be de-listed for failing to abide by U.S. accounting regulations. The SEC said YumC...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“ AstraZeneca ”) (L...
The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2021 Q4 earnings call. For further details see: HUTCHMED (China) Limited 2021 Q4 - Results - Earnings Call Presentation
Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%. ...
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HUTCHMED (China) Limited Website:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pati...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylig...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During t...